ArticleCirculation. Cardiovascular quality and outcomes2025
Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare.
Article in Circulation. Cardiovascular quality and outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcatheter Aortic Valve Replacement (TAVR) in Medicare Advantage and Medicare Fee-for-Service: Differences in Patient Characteristics, Utilization, and Outcomes.Circulation. Population health and outcomes · 2026Article
- The importance and challenge of comparing stroke care, utilization and outcomes in Medicare Advantage and Fee-for-Service Medicare: a narrative review and vision for the future.Journal of comparative effectiveness research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlthough cardiovascular disease is the leading cause of death in the United States among Medicare beneficiaries, management of modifiable risk factors remains suboptimal. Medicare Advantage (MA) enrollment has increased substantially; therefore, understanding the quality of cardiovascular risk factor management in MA is critical. In this study, we evaluated whether cardiovascular risk factor management was better among MA compared with traditional Medicare (TM) beneficiaries.
methodsWe linked physical examination and laboratory data from the National Health and Nutrition Examination Survey (2015-2018) to Medicare enrollment data. We calculated age- and sex-standardized differences for treatment and control rates of hypertension, diabetes, and hyperlipidemia among adults ≥65 years enrolled in MA compared with TM. National Health and Nutrition Examination Survey weights were used to calculate nationally representative estimates.
resultsThe weighted study population included 45 426 712 adults (34.4% MA, 65.6% TM). The mean age was 72.9 years and 55.3% were female. MA beneficiaries were more likely to be female (58.5% versus 53.5%), less likely to be White (71.7% versus 81.7%), and more likely to have household incomes <100% poverty (11.4% versus 7.0%). Treatment rates for hypertension (82.3% versus 79.1%; SD, 3.4 percentage points [pp]; [95% CI, -1.1 to 7.9]), hyperlipidemia (56.4% versus 56.0%; SD, 0.5 pp [95% CI, -5.7 to 6.8]), and diabetes (76.3% versus 82.5%; SD, -5.0 pp [95% CI, -13.1 to 3.1]) did not significantly differ between MA and TM beneficiaries. There were also no differences in control rates for hypertension (43.6% versus 46.1%; SD, -1.2 pp [95% CI, -8.8 to 6.4]), hyperlipidemia (51.5% versus 48.0%; SD, 4.0 pp [95% CI, -1.7 to 9.7]), and diabetes (61.5% versus 55.3%; SD, 4.4 pp [95% CI, -6.3 to 15.1]).
conclusionsDespite the rapid rise in MA enrollment among individuals with cardiovascular risk factors and disease over the past decade, treatment and control rates for hypertension, diabetes, and hyperlipidemia were similar between MA and TM beneficiaries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.